|
Cover Story
Snowden Makes Headlines
|
||
|
People of World Influence Washington Insider Touts
|
||
|
The Washington Diplomat Exclusive Azerbaijan Rolls Out Red Carpet
|
||
|
International Relations
Myanmar’s Envoy Seizes
|
||
|
International Affairs Before Turkey Clamped Down
|
||
|
The Rotunda: Foreign Affairs on Capitol Hill Conscience and Consequence: Royce’s
|
||
|
Politics Nations Keep Watchful Eye
|
||
|
Diplomacy South Africa’s Renovated Mission
|
||
|
Inside the Chamber US-ASEAN Business Council Seeks
|
||
|
Medical Tsunami of Pricey Specialty Drugs
|
||
|
Kris Balderston’s job as special representative for global partnerships took his domestic career global. Now he’s onto his next challenge: Washington general manager of FleishmanHillard, one of the world’s largest PR and communications firms.
Hundreds of state legislators, more than a dozen members of Congress and three former top White House aides all converged on Azerbaijan last month in what some media outlets derided as a costly junket. The Diplomat was there and has an inside account.
Myanmar’s first ambassador to the U.S. in more than 20 years talks about reintroducing his once-isolated pariah state to the world.
The story of press freedom in Turkey is — like the country’s larger evolution and recent descent into chaos — complicated.
Rep. Ed Royce (R-Calif.), chairman of the House Committee on Foreign Affairs, opens up about, what he thinks is right and wrong with the world, and how he hopes to right those wrongs as a legislator in a polarized Congress.
Immigration reform is grinding its way through the halls of Congress, and foreign nations have been quick to insert their own little perks into the sweeping legislation.
South Africa is renovating its mission in Washington to build a space that speaks to the country’s past traditions and future hopes.
The US-ASEAN Business Council works to link Americans with the 10 countries that form the Association of Southeast Asian Nations, home to 600 million people and a combined GDP of $2.1 trillion.
For the first time in 50 years, spending on prescription drugs actually dropped — but the cost of specialty medications is skyrocketing.